Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands
Article first published online: 15 JAN 2010
© 2009, International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
Value in Health
Volume 13, Issue 4, pages 375–380, June/July 2010
How to Cite
Essers, B. A.B., Seferina, S. C., Tjan-Heijnen, V. C.G., Severens, J. L., Novák, A., Pompen, M., Oron, U. H. and Joore, M. A. (2010), Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands. Value in Health, 13: 375–380. doi: 10.1111/j.1524-4733.2009.00683.x
- Issue published online: 30 JUN 2010
- Article first published online: 15 JAN 2010
- HER2-positive breast cancer;
- model-based economic evaluation;
Introduction: Geographic transferability of model-based cost–effectiveness results may facilitate and shorten the reimbursement process of new pharmaceuticals. This study provides a real world example of transferring a cost–effectiveness study of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer from the United Kingdom to The Netherlands.
Methods: Three successive steps were taken. Step 1: Collect available information with regard to the original model, and assess transferability using existing checklists. Step 2: Adapt transferability-limiting factors. Step 3: Obtain a country-specific estimate of cost–effectiveness.
Results: The structure of the UK model was transferable, although some of the model inputs needed adaptation. From a health-care perspective, the Dutch estimate amounted to €5828/quality-adjusted life-year gained. From a societal perspective, the incremental cost–effectiveness ratio was dominant.
Conclusion: Transferability of a model-based UK-study in three steps proved to be an efficient method to provide an early indication of the cost–effectiveness of trastuzumab and has led to the provisional reimbursement of the treatment.